DOD Biotech PCL (BKK:DOD-R) 5-Year EBITDA Growth Rate: 0.00% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BKK:DOD-R DOD Biotech PCL BKK:DOD-R
67 GF Score
Price ฿0.97
GF Value ฿1.52
! 6 Warning Signs
View Full Analysis

What is DOD Biotech PCL 5-Year EBITDA Growth Rate?

DOD Biotech PCL BKK:DOD-R -5.84% 67 5-Year EBITDA Growth Rate is 0.00% as of Jun. 2026. GuruFocus rates BKK:DOD-R with a GF Score™ of 67/100 and a GF Value™ of ฿1.52. The stock has 6 warning signs investors should review.

DOD Biotech PCL's EBITDA per Share for the three months ended in Jun. 2026 was ฿0.03.

During the past 12 months, DOD Biotech PCL's average EBITDA Per Share Growth Rate was -56.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of DOD Biotech PCL was 97.90% per year. The lowest was -34.40% per year. And the median was -1.05% per year.

DOD Biotech PCL  (BKK:DOD-R) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

DOD Biotech PCL 5-Year EBITDA Growth Rate Related Terms

BKK:DOD-R vs KHC, GIS: 5-Year EBITDA Growth Rate Comparison

For the Packaged Foods subindustry, DOD Biotech PCL's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DOD Biotech PCL 5-Year EBITDA Growth Rate vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, DOD Biotech PCL's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where DOD Biotech PCL's 5-Year EBITDA Growth Rate falls into.


BKK:DOD-R
67GF Score
DOD Biotech PCL BKK:DOD-R
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DOD Biotech PCL 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 0.00% mean?
DOD Biotech PCL (BKK:DOD-R) has a 5-Year EBITDA Growth Rate of 0.00% as of Jun. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for DOD Biotech PCL and its competitors.
Is DOD Biotech PCL's 5-Year EBITDA Growth Rate too high?
DOD Biotech PCL's current 5-Year EBITDA Growth Rate is 0.00%. Overall, DOD Biotech PCL has a GF Score™ of 67/100, reflecting its overall financial health beyond just this single metric.
How does DOD Biotech PCL's 5-Year EBITDA Growth Rate compare to KHC and GIS?
DOD Biotech PCL's 5-Year EBITDA Growth Rate of 0.00% can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Consumer Packaged Goods company?
A good 5-Year EBITDA Growth Rate depends on the Consumer Packaged Goods industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for DOD Biotech PCL and its competitors. DOD Biotech PCL's current 5-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DOD Biotech PCL stock overvalued right now?
DOD Biotech PCL (BKK:DOD-R) has a current 5-Year EBITDA Growth Rate of 0.00%. The stock's GF Value™ is ฿1.52, compared to a current price of ฿0.97 — trading 36.4% below its estimated fair value. The current 5-Year EBITDA Growth Rate is 0.00%. DOD Biotech PCL's overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For DOD Biotech PCL (BKK:DOD-R), the current 5-Year EBITDA Growth Rate is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is DOD Biotech PCL (BKK:DOD-R) Overvalued in 2026?

Based on GuruFocus' analysis, DOD Biotech PCL stock appears to be undervalued. The current stock price of ฿0.97 is trading 36.4% below its estimated GF Value™ of ฿1.52.

Key valuation signals for BKK:DOD-R:

  • 5-Year EBITDA Growth Rate: 0.00%
  • GF Value™: ฿1.52 vs. price of ฿0.97 (36.4% below fair value)
  • GF Score™: 67/100 with 6 warning signs

No single metric tells the full story. See the BKK:DOD-R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

DOD Biotech PCL Business Description

Other Exchanges DOD:Thailand
Address No. 111, Moo 2, Tumbol Taa jeen, Amphor Muengsamutsakhon, Samut Sakhon, THA, 74000
DOD Biotech PCL is principally engaged in the manufacture and distribution of food supplements and health drinks of all kinds. The group is principally engaged in the supplement business. Its operations are carried on only in Thailand. Its products include: Capsule; Gel; Jelly; Powder for making drinks; Concentrated water extract (Shot Drink); Softgel; Tablet; Probiotics; Gummies; and Direct-to-Mouth Packaging.
67GF Score

Get the complete analysis for BKK:DOD-R

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

฿0.97
Price
฿1.52
GF Value